Αρχική World News N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised... World News N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity Από Ogkologos - 23 Ιανουαρίου, 2026 530 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the I-PREDICT study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR New obesity strategy is a ‘landmark day for the nation’s health’... 27 Ιουλίου, 2020 7 Practical Tips for Taking Long-Term Medication 9 Ιανουαρίου, 2024 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma 7 Απριλίου, 2021 Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... 5 Νοεμβρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer